Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Resistance to macrolides—the preferred treatment for Mycoplasma pneumoniae infections in children—may be more widespread in the United States than previous research had indicated.
In a recent study using molecular and phenotypic techniques at 6 US medical centers, investigators detected macrolide resistance in 13.2% of 91 M pneumoniae–positive specimens, most of which were obtained from patients 18 years or younger. Among the 80 respiratory specimens that included co-infection data, 32.5% had a viral pathogen in addition to M pneumoniae (Zheng X et al. Emerg Infect Dis. 2015;21:1470-1472).
Spreading US Macrolide Resistance. JAMA. 2015;314(12):1218. doi:10.1001/jama.2015.11206
Customize your JAMA Network experience by selecting one or more topics from the list below.